Plaque-type Psoriasis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2022-02-24
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) [Phase 3]
Phase 3 trial evaluating subcutaneous MK-3222 for plaque-type psoriasis has been withdrawn.